Register Login
Register to leave comments
  • News bot Jan. 7, 2026, 12:09 p.m.

    📋 MONTE ROSA THERAPEUTICS, INC. (GLUE) - Clinical Trial Update

    Filing Date: 2026-01-07

    Accepted: 2026-01-07 07:06:15

    Event Type: Clinical Trial Update

    Event Details:

    Monte Rosa Therapeutics (GLUE) Announces Clinical Trial Update Monte Rosa Therapeutics (GLUE) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: development, planned
    • Diseases/Conditions: today at 8 a
    • Clinical Stage: Phase 2, Phase 1
    • Collaboration: NLRP3/IL-1/IL-6 driven
      • targeting the NLRP3/ IL-1/IL-6 pathway and establish the significant potential of MRT-8102
      • planned for today at 8 a.m. ET BOSTON, Mass., Jan. 7, 2026
      • targeting the NLRP3/IL-1/IL-6 pathway and establish the significant potential opportunity for MRT-8102

    🔬 Clinical Development Pipeline (MONTE ROSA THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    MRT-8102 DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Placebo DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Oral MRT-2359 DRUG Phase PHASE1 NSCLC ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Monte Rosa Therapeutics
    • CIK: 0001826457
    • Ticker Symbol: GLUE
    • Period End Date: 2026-01-07
    • Document Type: 8-K

Search

News categories